Download full report with analyst certification and important disclosures
Jun 22 2020, 07:20 IST/BST
With Poseida filing for IPO on NASDAQ, Malin is one step closer to crystallising value in this key priority asset. The IPO could become effective mid-late July. Recent IPO activity suggests that Poseida could list at a premium to its current implied valuation of c.$540m (at December 31st 2019), supported by progress made to date by the company and several potential clinical milestones over the coming months.
Jun 22 2020, 07:20 IST/BST